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ABSTRACT
The recognition of hereditary causes of primary hyperparathyroidism (pHPT) is important because clinical care and surveillance differ
significantly between sporadic and hereditary pHPT. In addition, the increasing number of genetic tests poses a challenge to classify
mutations as benign or pathogenic. Functional work-up of variants remains a mainstay to provide evidence for pathogenicity. We
describe a 52-year-old male patient with recurrent pHPT since age 35 years. Despite several neck surgeries with complete
parathyroidectomy, he experienced persistent pHPT, necessitating repeated surgery for a forearm autotransplant, which finally
resulted in unmeasurable parathyroid hormone (PTH) levels. Genetic testing revealed a new CDC73 variant (c.238-8G>A [IVS2-
8G>A]), initially classified as a variant of uncertain significance. Parathyroid tissue from the initial surgeries showed loss of
heterozygosity. Using an RT-PCR approach, we show that the mutation leads to the use of a cryptic splice site in peripheral
mononuclear cells. In addition, a minigene approach confirms the use of the cryptic splice site in a heterologous cell system. The
novel c.238-8G>A CDC73 variant activates a cryptic splice site, and the functional data provided justify the classification as a likely
pathogenic variant. Our results underscore the importance of functional work-up for variant classification in the absence of other
available data, such as presence in disease-specific databases, other syndromic clinical findings, or family history. In addition, the
presented case exemplifies the importance to consider a hereditary condition in young patients with pHPT, particularly those with
multi-gland involvement. © 2017 American Society for Bone and Mineral Research.
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Introduction
Primary hyperparathyroidism (pHPT) is a common disorderinvolving complications of the skeletal, renal, neurocogni-
tive, and cardiovascular systems.(1,2) pHPT is caused by benign
adenomas, multiglandular hyperplasia, and rarely, parathyroid
carcinoma. pHPT is usually sporadic but also occurs as part of
familial syndromes, particularly in young patients (in 10%
cases),(3) includingmultiple endocrine neoplasia syndromes and
hyperparathyroidism-jaw tumor (HPT-JT) syndrome.(1–4)
Herein, we present a patient with pHPT and recurrent
parathyroid disease, with a new germline splice site mutation
in the gene Cell Division Cycle 73 (CDC73, accession number
NM_024529). The CDC73 gene encodes the 531 amino acid
parafibromin tumor suppressor protein. Missense, frameshift
mutations and deletions in CDC73 have been reported in
autosomal dominant familial HPT-JT.(5–7) HPT-JT is characterized
by ossifying fibromas in the jaws and pHPT but also includes
uterine fibroids, renal disease, and renal tumors. pHPT-JT also
bares the risk of progressing to parathyroid cancer.
Clinical genetic testing often yields variants of uncertain
significance. Pathogenicity cannot be determined only by data
available in the literature, family history, epidemiological and
disease-specific databases, or in silico prediction mechanisms,
all of which are often uncertain. Functional evaluation of the
mutation, its effect on transcription, translation, and protein
function, remains a major resource for solid evidence of
pathogenicity.
Our study details the effects of a novel splice site mutation in
CDC73 on parafibromin protein translation and investigates loss
of heterozygosity phenomenon in a patient with recurrent pHPT.
Clinical Case
The index case was a 52-year-old male with a longstanding
history of kidney stones and diagnosed with pHPT at age
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35 years. The initial surgery removed two hyperplastic
parathyroid glands causing normalization of calcium levels.
Seven years later, the patient had recurrent pHPT and
underwent removal of two adenomatous glands and auto-
transplantation to the forearm. Since then, he had recurrence
of pHPT and two unsuccessful surgeries (3 and 6 years post-
implantation) to reduce parathyroid tissue in the forearm.
During regular surveillance, he was finally found to have
several small hypoechoic areas in the proximal brachioradialis
(Supplemental Fig. S1). Post-surgery, parathyroid tissue and
parathyroid hormone (PTH) levels were less than the
measurable range after removal. A small amount of parathy-
roid tissue was implanted into a subcutanaeous area. He did
not have a history of jaw tumors. Although the proband’s
family history was negative for pHPT, jaw tumors, or kidney
lesions, the mother did undergo a hysterectomy presumably
because of uterine fibroids. Initial genetic testing did not
reveal a mutation in MENIN but revealed the presence of a
germline intronic variant of uncertain significance (VUS) in
CDC73 c.238-8G>A (IVS2-8G>A).
Materials and Methods
Plasmids
Wild-type and mutant CDC73 DNA strings were synthesized
(GeneArt, Thermo Fisher,Waltham,MA, USA) and subcloned into
the pDUP4-1 minigene using ApaI and BglII/BamHI sites. The
mutant CDC73 string included the G>A mutation 6 bps
upstream of exon 3. Primer details are provided in Supplemental
Table S1.
RNA and DNA isolation
RNA and DNA were isolated using the RNeasy Plus Mini Kit
(Qiagen, Valencia, CA, USA) and Wizard Genomic DNA Purifica-
tion Kit (Promega, Madison, WI, USA), respectively. Genomic
DNA from formalin-fixed paraffin-embedded (FFPE) tissue was
purified using the All Prep DNA/RNA FFPE Kit (Qiagen).
Complementary DNA was generated from RNA using the High
Capacity Reverse Transcriptase Kit (Life Technologies, Carlsbad,
CA, USA).
PCR and sequence analyses
All PCR amplifications were performed using the HotStarTaq
DNA Polymerase Kit (Qiagen) and the touch-down protocol as
described elsewhere.(8) Primer sequences are provided in
Supplemental Table S1.
Immunohistochemistry
Sections from formalin-fixed, paraffin-embedded normal
thyroid and superior and inferior hyperparathyroid tissues
were incubated with primary mouse monoclonal anti-
parafibromin antibody (Santa Cruz Biotechnology, Dallas, TX,
USA) followed by secondary antibody (En Vision reagent,
Dako, Carpinteria, CA, USA). Slides were visualized using
3,30-diaminobenzidine tetrahydrochloride and H2O2 and
counterstained with hematoxylin.
Human subject research
The patient consented to the Cancer Genetics Registry (IRB
approval, HUM 00043430).
Results
Effect of the mutation on RNA splicing
Analysis of peripheral blood mRNA identified that the wild-type
and mutant transcripts were both expressed (Fig. 1A), the
mutant transcript being spliced 6 bp upstream to the exon. In
vitro functional analysis of the splice variants was performed
utilizing the pDUP4-1 minigene system (Fig. 1D, E). Cells
expressing the pDUP4-1/Mutant CDC73 displayed a splice
variant of CDC73, which was 6 base pairs longer than the wild
type CDC73 mRNA (Fig. 1E).
Loss of heterozygosity (LOH)
LOH analysis was conducted in the resected hyperparathyroid
tissue and in the unaffected, normal thyroid tissue. Genomic
DNA sequence analysis from formalin-fixed paraffin-embedded
parathyroid tumors (Fig. 2B, C) exhibited LOH, while it was
preserved in control thyroid tissue (Fig. 2A). Immunostaining
confirmed parafibromin in thyroid tissue (Fig. 2E) and loss of
expression in the parathyroid tissues (Fig. 2F, G).
Discussion
Herein we identified a patient with recurrent pHPT harboring a
potential splice site mutation in the tumor suppressor CDC73
(c.238-8G>A). This mutation has not been reported in other
patients, nor is it present in ExAC or 1000 genomes. Lack of
functional data characterized it as a “variant of uncertain
significance.” Recurrent pHPT despite polyglandular resection
was suggestive of a pathogenic nature of the variant. Peripherial
blood analysis identified the variant as present in the germline,
potentially causing a 6 bp premature splicing of exon 3, resulting
in premature protein translation. The use of the cryptic splice site
during post-transcriptional modification was confirmed by RT-
PCR of RNA from peripheral blood as well as in an in vitro
minigene approach. Finally, we show that all parathyroid tumors
showed LOH and absence of parafibromin protein. Together
these data provide sufficient evidence to classify this variant as
pathogenic.
The classification and interpretation of observed variants
poses a significant challenge. The American College of Medical
Genetics and Genomics has presented a useful system to classify
germline genetic variants,(9) using clinical observations, segre-
gation, databases, in silico prediction, and functional data.
Segregation analysis is of limited value in small families or in the
absence of any other clearly affected family members as in the
presented case. Within our patient’s pedigree there was no
individual with any parathyroid abnormality, only a report on his
mother, who had a hysterectomy, likely because of uterine
fibroids, which are also frequent in the general population.
Therefore, functional analysis proves an exceptionally useful tool
to provide evidence for pathogenicity of a germline variant.
Unfortunately, no other family members were available for
testing of the new CDC73 variant. However, clinical cascade
testing for asymptomatic family members should always be
recommended in patients diagnosed with a pathogenic germ-
line variant. In case of pHPT associated with MEN1 or MEN2, at-
risk family members will benefit from surveillance for other
associated manifestations, such as neuroendocrine, chromaffin,
or pituitary tumors. Although there is no general surveillance
protocol for CDC73-related disorders, yearly evaluation of
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parathyroid function and physical exam for jaw tumors should
be considered. In addition, baseline ultrasound of the kidneys
should be entertained. Furthermore, knowledge of a pathogenic
CDC73 mutation in an individual patient can lead to a lower
threshold for work-up of uterine fibroids or other tumors
possibly associated with the disorder, keeping in mind the likely
not fully defined associated tumor risks and penetrance with
CDC73 pathogenic variants.
A recent study has shown that predisposing germline
mutations can be found in up to 10% of young patients
with pHPT.(3) Treatment of patients with hereditary predisposi-
tion to pHPT such as MEN1 or CDC73-related disorders is
challenging, and genetic testing can be advantageous in order
to plan the right surgical procedure.(8) In hereditary pHPT, it
should be considered to leave tissue in place, where it can be
more easily surveilled and explored in the future.(10)
When performing surgery in patients with four-gland
parathyroid disease or hereditary predisposition to pHPT, it is
preferable to perform subtotal parathyroidectomy as opposed
to total parathyroidectomy with autotransplantation, leaving
Fig. 1. (A) Analyses of mRNA from peripheral blood indicated that both predicted (wild-type and mutant) transcripts were expressed. (B) Wild-type and
(C) predicted mutant CDC73 transcripts. (D) Subcloning strategy to generate minigenes for WT and mutant CDC73. (E) In vitro characterization of the
splice variants. The genetic fragment containing the wild-type and mutant intronic region and its successive exon were subcloned into the pDUP4-1
minigene vector and transfected in human embryonic kidney cells. Cells expressing the pDUP4-1/Mutant CDC73 displayed a splice variant of CDC73,
which was 6 base pairs longer than the wild-type CDC73 mRNA causing the inclusion of a premature “stop” codon.
Fig. 2. Loss of heterozygosity across tissues. PCR amplification and Sanger sequencing of genomic DNA from formalin-fixed paraffin-embedded (FFPE)
left superior and inferior parathyroid tumor tissues showed loss of heterozygosity (B, C), while it was preserved in control thyroid tissue (A).
Immunostaining for parafibromin confirmed protein expression in thyroid tissue (E) and loss of expression in the parathyroid adenoma tissues (F, G)
relative to the negative control (D).
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the equivalent of a single normal parathyroid gland. This
approach avoids complete hypoparathyroidism and longer
periods of hypocalcemia as well as the potential implantation of
autonomously functioning and potentially malignant parathy-
roid tissue. If necessary, parathyroid autotransplantation is best
accomplished by creation of two intramuscular (eg, brachior-
adialis muscle) or subcutaneous pockets and placement of 20 to
30mg of parathyroid tissue minced into 1 to 2mm pieces into
these pockets. Any remaining or autotransplanted parathyroid
should be marked for future reference. Future experience will
determine whether recombinant PTH will present an alternative
for treatment of hypoparathyroidism in the setting of transient
or permanent hypoparathyroidism.
Additionally, it remains important to define the penetrance of
associated pathologies in order to streamline preventive
surveillance in gene carriers. Our patient was diagnosed before
the availability of routine genetic testing and after a long history
of pHPT and surgical management. However, our case under-
scores the importance and eventual success of continuous
follow-up and repeated surgery.
In summary, we show that this novel intronic CDC73mutation,
c.238-8G>A, activates a cryptic splice site and underwent LOH in
this patient’s parathyroid adenomas. Together these findings
provide strong in vitro evidence to reclassify this mutation as a
pathogenic variant confirming our patient’s diagnosis of CDC73-
related disorder. In the future, genetic testing for young patients
with pHPT will likely be beneficial in order to aid in the right
treatment approaches.
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